Pharmaceuticals, Biotechnology and Life Sciences
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Elizabeth (Betsy) Nabel, M.D. has been appointed to the Company’s Board of Director…
– Evidence of biologic activity of GMI-1359 observed in Phase 1b clinical trial interim analysis
– Preclinical data highlight anti-tumor activity in pancreatic cancer model with GMI-1757, a novel galectin-3 antagonist
ROCKVILLE, Md.–(BUSINESS WIRE)–…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Elizabeth (Betsy) Nabel, M.D. has been appointed to the Company’s Board of Director…
CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced multiple presentatio…
CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced multiple presentatio…
CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced multiple presentatio…
Study to enroll 60 participants previously vaccinated with mRNA-1273 in Phase 2, to evaluate booster vaccine candidates against the B.1.351 variant first identified in South Africa
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Moderna, Inc. (Nasdaq: MRNA), a bio…
CINCINNATI–(BUSINESS WIRE)–Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) today announced that it will report its first quarter 2021 financial results after the market close on Monday, April 26, 2021. The Company will host a conference call the fo…
Company intends to use funds to support lenzilumab manufacturing and commercialization
BURLINGAME, Calif.–(BUSINESS WIRE)–Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an …
Lenzilumab™ clinical development program for COVID-19 advances from IND to completion of Phase 3 enrollment in fewer than 12 months
Company completes two equity offerings in 2020, including uplisting to Nasdaq, to fund manufacturing scale-up and c…